Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rambam Health Care Campus
• Treatments: Camptothecin; Gemcitabine; Irinotecan

Criteria

Inclusion Criteria:

• locally advanced pancreatic cancer

• performance status 0-2

• normal blood count and chemistry

• no previous chemotherapy or radiotherapy

Exclusion Criteria:

• serious concurrent systemic disease